πŸ‡ΊπŸ‡Έ FDA
Patent

US 11117970

Human antibodies to PD-L1

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11117970 (Human antibodies to PD-L1) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K39/3955, A61K39/39558